238 x 160
Minimal Residual Disease Testing Market Opportunities, Competitive Landscape & Forecast, 2026-2035
Market Insight: Precision Oncology Strengthens Demand for Minimal Residual Disease Testing
The global Minimal Residual Disease (MRD) Testing Market was valued at USD 3 billion in 2026 and is projected to reach USD 9.78 billion by 2036, expanding at a compound annual growth rate (CAGR) of 12.54% during 2027–2036. The market's expansion reflects the growing importance of molecular diagnostics in cancer management, particularly as healthcare providers increasingly prioritize sensitive disease monitoring, treatment-response assessment, and personalized therapeutic decisions.
MRD testing is gaining momentum because conventional diagnostic approaches may not detect extremely small populations of cancer cells that remain after treatment. Advanced molecular techniques, including polymerase chain reaction (PCR)-based assays and circulating tumor DNA (ctDNA) analysis, can help identify residual disease that may influence relapse risk and subsequent treatment decisions. This capability is particularly relevant in hematological malignancies, where monitoring disease at a molecular level can support more informed clinical management.
Regional Analysis: North America Leads While Asia Pacific Creates New Growth Opportunities
North America held 48.92% of the global MRD testing market in 2026, supported by advanced oncology diagnostics, widespread molecular testing adoption, and the integration of disease monitoring into treatment decisions. In contrast, Asia Pacific is projected to expand at a 12.66% CAGR, reflecting the region's growing precision oncology capabilities, improving laboratory infrastructure, and increasing use of molecular diagnostics in routine cancer care.
North America's leadership is closely linked to its established diagnostic ecosystem. Specialized laboratories, access to advanced testing technologies, established oncology centers, and the development of clinical evidence have helped create favorable conditions for MRD testing. Reimbursement progress and the incorporation of molecular tests into clinical workflows can further strengthen adoption by reducing barriers for healthcare providers and patients.
The region also offers opportunities for companies seeking to commercialize sophisticated assays and expand partnerships with hospitals, diagnostic laboratories, pharmaceutical developers, and oncology networks. Nevertheless, providers must demonstrate clinical value and address differences in coverage and access across healthcare systems.
Asia Pacific presents a different opportunity. Its growth potential is associated with expanding healthcare infrastructure, increasing investment in cancer diagnostics, and the gradual adoption of precision medicine. As more healthcare institutions develop molecular testing capabilities, demand may broaden beyond major specialist centers into a wider range of clinical settings.
Industry Challenge: Reimbursement and Clinical Validation Remain Critical to Wider MRD Adoption
Despite the growing clinical relevance of MRD testing, broader adoption depends on overcoming several interconnected challenges. High analytical sensitivity alone does not guarantee routine clinical use. Healthcare providers must understand how a test result affects treatment decisions, while payers need evidence that testing delivers sufficient clinical and economic value.
One of the principal challenges is demonstrating clinical utility across different cancer types and treatment settings. A test may identify residual disease at very low levels, but clinicians still need evidence explaining how results should guide treatment selection, monitoring frequency, or follow-up strategies. The significance of a positive or negative result can vary according to the disease, assay methodology, and clinical context.
Reimbursement is another important consideration. Testing costs, inconsistent coverage policies, and differences in healthcare funding can restrict patient access, even when a technology demonstrates promising analytical performance. Expanded reimbursement, such as the coverage development reported for Personalis, can help address this challenge by improving the commercial viability of testing and facilitating integration into clinical workflows.
Laboratory standardization also presents operational difficulties. Differences in assay design, sample handling, analytical sensitivity, and reporting practices can complicate comparisons between tests. Healthcare providers need confidence that results are reproducible and clinically interpretable before incorporating them into established care pathways.
Product and Technology Comparison: PCR-Based MRD Testing Versus ctDNA-Based Monitoring
PCR-based assays and circulating tumor DNA (ctDNA)-based testing represent important approaches within the MRD testing landscape. Both support molecular disease assessment, but their underlying methodologies, clinical applications, and implementation requirements can differ. The most appropriate approach depends on the cancer type, the molecular targets being monitored, the intended clinical use, and the evidence supporting the assay.
|
Comparison factor |
PCR-based testing |
ctDNA-based testing |
|
Core approach |
Detects specific genetic sequences using amplification-based methods |
Analyzes tumor-associated DNA fragments circulating in the blood |
|
Key advantage |
Targeted detection with established molecular laboratory workflows |
Potential to monitor tumor-associated molecular changes through a blood sample |
|
Important consideration |
Performance depends on the selected targets and assay design |
Detection depends on tumor DNA availability, assay sensitivity, and the clinical context |
|
Potential applications |
Targeted residual disease detection and longitudinal molecular monitoring |
Molecular monitoring, recurrence assessment, and selected applications in precision oncology |
|
Commercial opportunity |
Expanding established diagnostic platforms into MRD applications |
Developing sensitive assays and integrated liquid-biopsy testing services |
PCR-based testing benefits from established laboratory expertise and its ability to detect specific molecular targets with high sensitivity when appropriately designed and validated. Its established technical foundation can make it attractive for laboratories seeking to expand molecular oncology services. However, assay performance depends on target selection, and testing may be less suitable when the relevant molecular targets are not adequately characterized or covered by the assay.
ctDNA-based monitoring offers a different approach by examining tumor-associated DNA fragments in blood. This can support less invasive molecular monitoring and may provide insights into disease status over time. Its clinical usefulness, however, depends on factors such as tumor DNA shedding, disease characteristics, sample quality, and analytical sensitivity. A negative result does not necessarily exclude residual disease.
Geographic Opportunity: Four Markets to Watch in MRD Testing
Country-level opportunities depend on oncology infrastructure, access to molecular diagnostics, healthcare funding, and the availability of validated testing services. The following markets offer distinct strategic considerations for MRD testing companies, although the precise commercial opportunity will vary by country and clinical application.
United States: Clinical adoption and commercial development
The United States is a strategic market for companies seeking to commercialize advanced molecular oncology diagnostics. Established specialist laboratories, oncology networks, and diagnostic innovation provide an environment for developing and evaluating MRD testing services.
The expansion of reimbursement coverage and integration into recognized clinical pathways can help support adoption. Companies should prioritize clinical evidence, payer engagement, and partnerships with hospitals and specialist laboratories. Demonstrating how test results influence patient management will be particularly important for sustained commercial uptake.
China: Expanding molecular diagnostics capabilities
China presents a potential opportunity through the development of cancer diagnostic infrastructure and the broader adoption of precision medicine. Greater availability of advanced laboratories can create opportunities for molecular monitoring services across selected oncology settings.
Market entry requires careful attention to local regulatory requirements, healthcare procurement practices, pricing, and competition from domestic diagnostic providers. Partnerships with local laboratories and healthcare institutions may help international companies adapt their testing services to local requirements.
Japan: Advanced healthcare and precision oncology
Japan offers a strategic setting for MRD testing through its established healthcare infrastructure and interest in advanced diagnostic technologies. Potential applications include molecular monitoring in specialist oncology care and the integration of validated assays into established treatment pathways.
Commercial success will depend on clinical evidence, regulatory compliance, reimbursement considerations, and collaboration with healthcare providers. Companies should focus on demonstrating the practical value of testing within the country's clinical and laboratory systems.
India: Expanding access to molecular cancer diagnostics
India offers potential for expanding access to molecular diagnostics as specialized cancer centers and diagnostic laboratory capabilities develop. MRD testing providers may find opportunities in partnerships with tertiary hospitals, reference laboratories, and oncology networks.
Affordability is an important consideration. Testing models that combine reliable analytical performance with accessible pricing, efficient sample transportation, and appropriate laboratory infrastructure may be better suited to broader implementation. Education for clinicians and clear reporting practices can also support confidence in molecular monitoring.
Competitive Landscape: Companies Compete Through Financing, Reimbursement, Partnerships, and Technology Innovation
Competition in the MRD testing market is increasingly shaped by more than assay development alone. Companies are pursuing different strategies, including securing financing, expanding reimbursement coverage, forming commercial alliances, investing in cancer profiling technologies, and improving laboratory capabilities. These developments indicate that market participants recognize the need to connect technological innovation with clinical adoption and commercial scalability.
Countable Labs: Financing to accelerate molecular diagnostic development
In May 2026, Countable Labs secured $26 million in financing to accelerate the development and global commercialization of its single-molecule PCR technology. The investment supports the expansion of its molecular diagnostic capabilities, with applications targeting clinical product development and cancer monitoring.
Lucence: Collaborative investment in cancer profiling
In March 2026, Lucence, in partnership with DXD Hub and NCCS, initiated the $6 million UNITED 2.0 program to develop next-generation cancer profiling technologies.
The initiative demonstrates the role of collaborative research in advancing molecular diagnostics. Partnerships can combine scientific expertise, institutional capabilities, and development resources, potentially accelerating innovation in areas relevant to precision oncology and MRD testing. Such collaborations may also help build the evidence needed for future clinical applications.
NeoGenomics: Commercial partnerships to expand MRD monitoring
In January 2025, NeoGenomics entered a multi-year exclusive strategic commercial partnership with Adaptive Biotechnologies to scale MRD monitoring solutions for patients with specific blood cancers.
The partnership illustrates how companies can use complementary capabilities to extend the reach of specialized diagnostic services. Commercial alliances may help improve access to validated technologies, strengthen laboratory service offerings, and accelerate adoption in hematological oncology. They also demonstrate the value of collaboration when independent development or commercialization would require substantial resources.
Foresight Diagnostics: Guideline inclusion as a route to adoption
In January 2025, Foresight Diagnostics secured inclusion of its ctDNA-MRD testing technology in the National Comprehensive Cancer Network (NCCN) Guidelines for diffuse large B-cell lymphoma.
Guideline inclusion can strengthen the clinical visibility of a diagnostic technology and support its consideration within established care pathways. However, the commercial impact still depends on the applicable recommendation, clinical circumstances, reimbursement, and implementation practices. For diagnostic developers, building strong evidence and aligning with recognized clinical standards can be as important as developing technically advanced assays.
Recent Industry News: Key Developments Shaping MRD Testing (September 2024–May 2026)
Recent industry developments highlight the growing importance of commercial execution, clinical integration, and technological innovation in molecular cancer diagnostics. The following announcements illustrate how market participants are addressing different requirements for MRD testing adoption.
May 2026
Countable Labs secures $26 million in financing
Countable Labs secured financing to advance its single-molecule PCR technology and accelerate global commercialization. The announcement underscores the importance of investment in assay development, product readiness, and commercial expansion. It also reflects investor interest in specialized molecular diagnostic technologies for oncology applications.
May 2026
Personalis expands CMS reimbursement coverage
Personalis achieved expanded CMS reimbursement coverage for its NeXT Personal MRD test for cancer immunotherapy monitoring. The development highlights reimbursement as a practical driver of access and adoption. It also reinforces the importance of aligning diagnostic innovation with payer requirements and clinical utility.
March 2026
Lucence launches the UNITED 2.0 cancer profiling program
Lucence, DXD Hub, and NCCS initiated a $6 million program focused on next-generation cancer profiling. The collaboration illustrates the value of combining institutional research capabilities to advance molecular diagnostics and strengthen the development pipeline for precision oncology technologies.
January 2025
NeoGenomics expands its MRD monitoring partnership
NeoGenomics formed a multi-year exclusive commercial partnership with Adaptive Biotechnologies to scale MRD monitoring solutions for selected blood cancers. The agreement demonstrates how strategic alliances can expand market reach and connect specialized technologies with established diagnostic service capabilities.
January 2025
Foresight Diagnostics gains NCCN Guidelines inclusion
Foresight Diagnostics secured inclusion of its ctDNA-MRD testing technology in the NCCN Guidelines for diffuse large B-cell lymphoma. The development highlights the strategic value of clinical recognition and evidence-based guidance in supporting the adoption of specialized molecular tests.
Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/minimal-residual-disease-testing-market-14527
About
Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
Read This Report in Regional Languages -
